Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60
Rahul Kumar, Ajay K. Chaudhary, Jordan Woytash, Joseph R. Inigo, Abhiram A. Gokhale, Wiam Bshara, Kristopher Attwood, Jianmin Wang, Joseph A. Spernyak, Eva Rath, Neelu Yadav, Dirk Haller, David W. Goodrich, Dean G. Tang, Dhyan Chandra
Rahul Kumar, Ajay K. Chaudhary, Jordan Woytash, Joseph R. Inigo, Abhiram A. Gokhale, Wiam Bshara, Kristopher Attwood, Jianmin Wang, Joseph A. Spernyak, Eva Rath, Neelu Yadav, Dirk Haller, David W. Goodrich, Dean G. Tang, Dhyan Chandra
View: Text | PDF
Research Article Cell biology Oncology

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60

  • Text
  • PDF
Abstract

Mitochondrial proteostasis, regulated by the mitochondrial unfolded protein response (UPRmt), is crucial for maintenance of cellular functions and survival. Elevated oxidative and proteotoxic stress in mitochondria must be attenuated by the activation of a ubiquitous UPRmt to promote prostate cancer (PCa) growth. Here we show that the 2 key components of the UPRmt, heat shock protein 60 (HSP60, a mitochondrial chaperonin) and caseinolytic protease P (ClpP, a mitochondrial protease), were required for the development of advanced PCa. HSP60 regulated ClpP expression via c-Myc and physically interacted with ClpP to restore mitochondrial functions that promote cancer cell survival. HSP60 maintained the ATP-producing functions of mitochondria, which activated the β-catenin pathway and led to the upregulation of c-Myc. We identified a UPRmt inhibitor that blocked HSP60’s interaction with ClpP and abrogated survival signaling without altering HSP60’s chaperonin function. Disruption of HSP60-ClpP interaction with the UPRmt inhibitor triggered metabolic stress and impeded PCa-promoting signaling. Treatment with the UPRmt inhibitor or genetic ablation of Hsp60 inhibited PCa growth and progression. Together, our findings demonstrate that the HSP60-ClpP–mediated UPRmt is essential for prostate tumorigenesis and the HSP60-ClpP interaction represents a therapeutic vulnerability in PCa.

Authors

Rahul Kumar, Ajay K. Chaudhary, Jordan Woytash, Joseph R. Inigo, Abhiram A. Gokhale, Wiam Bshara, Kristopher Attwood, Jianmin Wang, Joseph A. Spernyak, Eva Rath, Neelu Yadav, Dirk Haller, David W. Goodrich, Dean G. Tang, Dhyan Chandra

×

Figure 5

Ablating key UPRmt components inhibits PCa development and growth in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Ablating key UPRmt components inhibits PCa development and growth in viv...
(A and B) Parental DU145 and Hsp60+/– DU145 cells were transplanted into SCID mice. Xenograft tumors were harvested and photographed (A) and weighed, with the results presented in grams (B). (C) Whole-cell lysates (WCLs) from parental and Hsp60+/– DU145 xenografts were analyzed for HSP60 and ClpP by Western blotting. (D) Hsp60- or ClpP-silenced PC-3 cells were transplanted into SCID mice. Xenografts were harvested and photographed. (E) Hsp60- or ClpP-silenced PC-3 cells were transplanted into SCID mice. Tumor size was checked every 4 days and is represented as tumor volume (mm3). (F) HSP60 and ClpP silencing efficiency in PC-3 cell xenografts was determined using Western blotting. T, tumor. (G) WT, PB-Cre4 Hsp60fl/fl, TKO, TKO Hsp60fl/+, and TKO Hsp60fl/fl prostate tissue and tumors were harvested at 16 weeks of age and the whole genitourinary (GU) tract was weighed and is presented in grams. (H) WT, PB-Cre4 Hsp60fl/fl, TKO, TKO Hsp60fl/+, and TKO Hsp60fl/fl prostates were imaged by MRI and outlined as indicated (green, normal seminal vesicle [SV]; red, normal prostate; magenta, urethra; yellow, prostate tumor; blue, SV tumor). Mouse prostate tissue and tumors were harvested at 16 weeks and representative H&E-stained images are shown. Scale bar: 100 μm. (I and J) WT, PB-Cre4 Hsp60fl/fl, TKO, TKO Hsp60fl/+, and TKO Hsp60fl/fl prostate tissue and tumors were harvested at 16 weeks of age and WCLs were prepared and analyzed for HSP60 and ClpP (I) and c-Myc and EZH2 (J) by Western blotting. (K) ATP levels and (L) ATP/ADP ratio were analyzed in WT, TKO, TKO Hsp60fl/+, and TKO Hsp60fl/fl prostate tissue, represented as fold change compared to WT tissue. Data are mean ± SD (n ≥ 3). *P < 0.05 by 1-way ANOVA followed by Dunnett’s multiple-comparison test (B and E). *P < 0.05; #P < 0.05 by 1-way ANOVA followed by Tukey’s multiple-comparison test (G, K, and L). Actin serves as a loading control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts